Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul 1;4(4):449-467.
doi: 10.2217/fnl.09.17.

Transglutaminase activation in neurodegenerative diseases

Thomas M Jeitner  1 , Nancy A Muma, Kevin P Battaile, Arthur Jl Cooper
Affiliations

Transglutaminase activation in neurodegenerative diseases

Thomas M Jeitner et al. Future Neurol. .

Abstract

The following review examines the role of calcium in promoting the in vitro and in vivo activation of transglutaminases in neurodegenerative disorders. Diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease exhibit increased transglutaminase activity and rises in intracellular calcium concentrations, which may be related. The aberrant activation of transglutaminase by calcium is thought to give rise to a variety of pathological moieties in these diseases, and the inhibition has been shown to have therapeutic benefit in animal and cellular models of neurodegeneration. Given the potential clinical relevance of transglutaminase inhibitors, we have also reviewed the recent development of such compounds.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Closed state of TG 2
The secondary structure of the closed form of TG 2 (PDB 1KV3) is rendered as a ribbon inside the molecular surface of the protein with an associated GDP depicted in a ball-and-stick configuration.
Figure 2
Figure 2. Active state of TG 2 with exposed active site
The secondary structure of the unfolded active form of TG 2 (PDB 2Q3Z) is rendered as a ribbon inside the molecular surface of the protein.
Figure 3
Figure 3. Calcium-binding site 1 in TG 3
The coordinating residues for the calcium bound to site 1 of TG 3 (PDB 1L9N) are rendered as a ribbon, and residues Ala221, Asn224, Asn226 and Asp228 are shown in a ball-and-stick configuration around the calcium. The molecular surface of the protein is shown in yellow. It should be noted that the calcium at this site is almost fully enveloped inside the surface of the protein.
Figure 4
Figure 4. Calcium-binding site 2 in TG 3
The coordinating residues for the calcium bound to site 2 of TG 3 in both the calcium bound (PDB 1L9N) and calcium free (PDB 1L9M) are shown. The backbone of the bound state is rendered in blue and the free state is rendered in green, as are the atoms with the calcium rendered as in CPK. The residues involved are Asn393, Ser415, Glu443 and Glu448. It should be noted that there is significant motion of Asn393 and Glu443 upon calcium binding.
Figure 5
Figure 5. Calcium-binding site 3 in TG 3
The coordinating residues for the calcium bound to site 3 of TG 3 in both the calcium-bound (PDB 1L9N) and calcium-free state (PDB 1L9M) are shown. The backbone of the bound state is rendered in blue and the free state is rendered in green, as are the atoms with the calcium rendered as in CPK. The residues involved are Asp301, Asp303, Asn305, Ser307 and Asp324. Of note, there is significant motion of Asp324 in this binding site, which in the free state is significantly displaced from its position in the bound state.
See this image and copyright information in PMC

References

    1. Kim SY, Grant P, Lee JH, et al. Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J. Biol. Chem. 1999;274:30715–33021. [■■ of considerable interestFirst study to demonstrate that at least three transglutaminases (TGs) are present in human brain and that Alzheimer's disease (AD) brain has greatly increased levels of protein crosslinks.] - PubMed
    1. Citron BA, SantaCruz KS, Davies PJA, et al. Intron–exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease. J. Biol. Chem. 2001;276:3295–3301. - PubMed
    1. Wilhelmus MM, Grunberg SC, Bol JG, et al. Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer's disease brain. Brain Pathol. 2008 DOI: 10.1111/j.1750−3639.2008.00197.x. (Epub ahead of print) [■ of interestImportant demonstration of TGs and pathological lesions in AD brain.] - PMC - PubMed
    1. Hadjivassiliou M, Aeschlimann P, Strigun A, et al. Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann. Neurol. 2008;64:332–343. [■ of interestDemonstration of TG 6 in human brain.] - PubMed
    1. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 2003;4:140–156. - PubMed